BRP
Novel appetite-suppressing peptide targeting ghrelin acylation — very early preclinical stage.
Research facts
| Half-life | Unknown |
|---|---|
| Route | IV / SubQ (animal studies only) |
| Typical dose | No established human dose |
| Frequency | Unknown |
| Solvent | N/A |
| pH | N/A |
| Stability | Unknown |
Mechanism of action
BRP (Beta-Rug Peptide) is an emerging research compound targeting ghrelin O-acyltransferase (GOAT) — the enzyme responsible for the acylation of ghrelin (the active modification that enables ghrelin to activate the GHS-R1a receptor and stimulate appetite/GH release). By inhibiting GOAT, BRP reduces active (acylated) ghrelin levels, potentially suppressing appetite and the ghrelin-driven GH pulse. In animal models, GOAT inhibition has shown promising appetite reduction and metabolic effects.
Documented effects (research-model)
- Novel GOAT-inhibitory mechanism for appetite control
- Reduces active acyl-ghrelin (the appetite-stimulating form)
- Potential complement to GLP-1 agonist therapy
- Research tool for understanding ghrelin biology
Research protocols
| Protocol | Dose | Frequency | Cycle | Vial |
|---|---|---|---|---|
| Research Only | No human dose | N/A | N/A | N/A |
Research context only. Not medical advice. Consult a qualified healthcare professional before any protocol decision.
Synergies
No documented synergies in the current reference set.
Myths & misconceptions
Evidence gaps
- Essentially all aspects of human pharmacology are unknown.
- Whether GOAT inhibition produces desired effects without disrupting GH pulsatility is unclear.
Safety notes
No human data. Educational profile only.
Biomarkers to monitor
Primary-source citations
- PMID 23271707 — Ghrelin O-acyltransferase inhibition: a new strategy for metabolic regulation (Nat Chem Biol. 2013)
Frequently asked
What is BRP?
BRP (Beta-Rug Peptide (BRP) — Ghrelin O-Acyltransferase Inhibitor) is a research compound classified in our library as Tier D — Animal or in-vitro data only.. Novel appetite-suppressing peptide targeting ghrelin acylation — very early preclinical stage.
What is the evidence tier for BRP?
We classify BRP as Tier D: Animal or in-vitro data only. See our full peptide evidence tiers explainer for how we assign S/A/B/C/D.
What is the research dose of BRP?
For BRP, typical research dose is No established human dose, route is IV / SubQ (animal studies only), half-life is Unknown. Protocols vary by research goal — see the protocols section on this page for standard and advanced dosing schedules. Research use only, not medical advice.
Is BRP safe?
No human data. Educational profile only. Research context only — no compound on this site is approved for human therapeutic use unless explicitly noted.